Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Eur J Dermatol ; 32(5): 615-617, 2022 09 01.
Article in English | MEDLINE | ID: mdl-36468738

ABSTRACT

Background: The COVID-19 pandemic has influenced health care services all around the globe, which is also reflected in the diagnosis and management of malignant melanoma (MM). Objectives: We performed a retrospective assessment of the impact of the COVID-19 pandemic on the diagnosis of MM in order to evaluate the effects of the pandemic on MM care. Materials & Methods: The Breslow thickness of excised MM and total number of patients with newly diagnosed MM who underwent surgery during the first year of the pandemic (March, 2020 to February, 2021; 227 subjects) were compared relative to a control period the year before (March, 2019 to February, 2020; 201 subjects), based on a retrospective study design. Results: There was no significant decrease in the total number of excisions (227 subjects in the pre-COVID cohort vs. 201 in the COVID cohort). However, the mean Breslow thickness increased significantly from 1.1±1.4 mm in the pre-COVID group to 1.8±2.3 mm in the COVID group. Conclusion: We conclude that, due to several restrictions in the early phase of the pandemic, melanomas were diagnosed at a more advanced stage.


Subject(s)
COVID-19 , Melanoma , Humans , Retrospective Studies , Pandemics , Melanoma/diagnosis , Melanoma/epidemiology , Melanoma/surgery , Melanoma, Cutaneous Malignant
2.
Case Rep Dermatol ; 14(3): 356-361, 2022.
Article in English | MEDLINE | ID: mdl-36655064

ABSTRACT

Lichen planus is a chronic, inflammatory, immune-mediated dermatosis affecting the patient's skin, scalp, mucous membranes, and nails. Drug-induced lichen planus is described after the administration of antimalarials, ß-blockers, methyldopa, NSAIDs, penicillamines, and sodium aurothiomalate. The use of biologicals such as adalimumab, etanercept, and infliximab has also been linked with the appearance of lichenoid eruptions in the recent past. In this case, we report on a patient developing oral and cutaneous lichen planus after the administration of dupilumab. The lichenoid lesions occurred after 11 months of the drug's administration and involved the buccal walls, trunk, and extremities. Dupilumab had been administered in an effort to counter severe atopic dermatitis exacerbations. Dupilumab is associated with a downregulation of T-helper 2 cell activation by blocking the Interleukin-4/Interleukin-13 pathway, so leading to a TH1/TH2 imbalance. This imbalance may cause a shift toward a TH1-mediated immune response and be an explanation for the drug-induced lichen planus. Dupilumab was discontinued, and the patient was treated with oral corticosteroids and UVB phototherapy, leading to a significant improvement in the lichen planus lesions.

10.
Case Rep Dermatol ; 9(3): 225-230, 2017.
Article in English | MEDLINE | ID: mdl-29282396

ABSTRACT

Squamous cell carcinoma (SCC) is the second most common type of skin cancer after basal cell carcinoma (BCC). The overall prevalence of BCC is 3 times higher than that of SCC, but this can vary when looking at specific locations such as the hand, where SCC is much more common than BCC. Carcinoma (or epithelioma) cuniculatum is a rare variant of SCC. It was originally described as a verrucous carcinoma of the soles. Exceptionally, it can arise in other parts of the skin. We report a rare case of carcinoma cuniculatum of the right thenar region with bone and lymph node involvement.

11.
PLoS One ; 9(1): e84417, 2014.
Article in English | MEDLINE | ID: mdl-24489649

ABSTRACT

Malignant melanoma is a life-threatening skin cancer increasingly diagnosed in the western world. In advanced disease the prognosis is grave. Growth and metastasis formation in melanomas are regulated by a network of cytokines, cytokine-receptors, and adhesion molecules. However, little is known about surface antigens and target expression profiles in human melanomas. We examined the cell surface antigen profile of human skin melanoma cells by multicolor flow cytometry, and compared their phenotype with 4 melanoma cell lines (A375, 607B, Mel-Juso, SK-Mel28). Melanoma cells were defined as CD45-/CD31- cells co-expressing one or more melanoma-related antigens (CD63, CD146, CD166). In most patients, melanoma cells exhibited ErbB3/Her3, CD44/Pgp-1, ICAM-1/CD54 and IGF-1-R/CD221, but did not express CD20, ErbB2/Her2, KIT/CD117, AC133/CD133 or MDR-1/CD243. Melanoma cell lines were found to display a similar phenotype. In most patients, a distinct subpopulation of melanoma cells (4-40%) expressed the erythropoietin receptor (EPO-R) and ErbB4 together with PD-1 and NGF-R/CD271. Both the EPO-R+ and EPO-R- subpopulations produced melanoma lesions in NOD/SCID IL-2Rgamma(null) (NSG) mice in first and secondary recipients. Normal skin melanocytes did not express ErbB4 or EPO-R, but expressed a functional KIT receptor (CD117) as well as NGF-R, ErbB3/Her3, IGF-1-R and CD44. In conclusion, melanoma cells display a unique composition of surface target antigens and cytokine receptors. Malignant transformation of melanomas is accompanied by loss of KIT and acquisition of EPO-R and ErbB4, both of which are co-expressed with NGF-R and PD-1 in distinct subfractions of melanoma cells. However, expression of EPO-R/ErbB4/PD-1 is not indicative of a selective melanoma-initiating potential.


Subject(s)
ErbB Receptors/genetics , Gene Expression Regulation, Neoplastic , Melanoma/genetics , Receptor, Nerve Growth Factor/genetics , Receptors, Erythropoietin/genetics , Skin Neoplasms/genetics , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Cell Line, Tumor , ErbB Receptors/metabolism , Female , Flow Cytometry , Humans , Immunophenotyping , Male , Melanoma/metabolism , Melanoma/pathology , Mice , Mice, Inbred NOD , Neoplasm Transplantation , Programmed Cell Death 1 Receptor/genetics , Programmed Cell Death 1 Receptor/metabolism , Proto-Oncogene Proteins c-kit/deficiency , Proto-Oncogene Proteins c-kit/genetics , Receptor, ErbB-4 , Receptor, Nerve Growth Factor/metabolism , Receptors, Erythropoietin/metabolism , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
12.
J Antimicrob Chemother ; 68(4): 895-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23212112

ABSTRACT

OBJECTIVES: Ertapenem pharmacokinetics were determined in the interstitium of healthy tissue and of infected tissue of patients suffering from diabetic foot infections, to evaluate if antibiotic concentrations at the target site are sufficient to achieve bacterial killing. PATIENTS AND METHODS: Nine patients with diabetic foot infections received 1 g of ertapenem per day intravenously. At steady-state, ertapenem concentrations were measured over 8 h in plasma and in the interstitium of healthy subcutaneous adipose tissue and of soft tissue adjacent to the foot infection using microdialysis. RESULTS: The maximum total concentration (Cmax) of ertapenem in plasma was 59.4 ± 12.9 mg/L. Free interstitial Cmax in the infected leg (4.5 ± 2.7 mg/L) was significantly higher (P=0.01) than in healthy subcutaneous tissue (2.4 ± 1.6 mg/L). For bacterial pathogens with an MIC of 1 mg/L, the free mean 'time above MIC' (T>MIC) in the interstitium of infected tissue was calculated to be 38%± 25% of the 24 h dosing interval. Accordingly, bacteriostatic (T>MIC >20%) and maximal bactericidal (T>MIC >40%) effects would be reached in 8/9 and 4/9 diabetic feet, respectively. CONCLUSIONS: Although total plasma concentrations of ertapenem were lower in diabetics than reported for healthy subjects, free interstitial tissue concentrations in diabetics were similar to those known from healthy volunteers. Penetration of ertapenem into the interstitium of inflamed tissue of diabetic feet was not impaired in spite of angiopathy. Daily doses of >1 g of ertapenem might be considered to optimize bactericidal effects in diabetic foot infections caused by moderately susceptible strains.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Bacterial Infections/drug therapy , Diabetic Foot/complications , Skin/chemistry , beta-Lactams/administration & dosage , beta-Lactams/pharmacokinetics , Administration, Intravenous , Adolescent , Adult , Aged , Aged, 80 and over , Ertapenem , Female , Humans , Male , Middle Aged , Plasma/chemistry , Skin/pathology , Young Adult
13.
Br J Clin Pharmacol ; 74(5): 806-14, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23227470

ABSTRACT

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes. Critically ill patients have significantly lower plasma anti-factor-Xa activity levels compared with control patients after administration of subcutaneous heparin. The clinical relevance of the different anti-factor-Xa levels after prophylactic doses of low molecular weight heparin (LMWH) in critically ill patients is not completely understood. WHAT THIS STUDY ADDS: The standard dose of 40 mg enoxaparin led to a significant increase in anti-FXa levels in this selected cohort of ICU patients with normal renal function. This study found only subtle pharmacokinetic differences, but a comparable pharmacodynamic action, after enoxaparin administration in critically ill and normal medical ward patients. Thrombin generation with TGA RC-low and TGARC-high reagents was significantly reduced in ICU and normal ward patients after receiving LMWH. Both readouts appear equally useful for estimating the pharmacodynamics of enoxaparin. The ex vivo model of thrombosis was used for the first time in patients to evaluate the anti-thrombotic activity of LMWH. This method did not show any difference in thrombus formation after administration of enoxaparin in the individual group of patients. AIM: In critically ill patients, reduced anti-FXa plasma activity following subcutaneous administration of enoxaparin or nadroparin has been described. In this study, we aimed to investigate the bioactivity of enoxaparin in critically ill patients and controls. METHODS: A prospective, controlled, open label study was performed on a medical intensive care unit (ICU) and a general medical ward. Fifteen ICU patients (male = 12, median age 52 years [IQR 40-65], with a median Simplified Acute Physiology Score of 30 [IQR 18-52]) and sex- and age-matched medical ward patients were included. The anti-FXa plasma activity was measured after a single subcutaneous dose of40 mg enoxaparin. The thrombus size of a clot formed in an ex vivo perfusion chamber and endogenous thrombin potential (ETP) were measured. RESULTS: The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13). The area under the anti-FXa activity curve from 0­12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively). The ETP was lower in the ICU group (P < 0.05) at baseline, but it was comparable at 3 h between the groups. Thrombus size decreased at 3 h compared with pre-dose (P = 0.029) and was not different between the groups. CONCLUSION: Similar bioactivity was achieved with a standard dose of subcutaneous enoxaparin in this selected cohort of ICU and general ward patients with normal renal function.


Subject(s)
Anticoagulants/pharmacology , Enoxaparin/pharmacology , Factor Xa Inhibitors , Venous Thromboembolism/prevention & control , Adult , Aged , Anticoagulants/pharmacokinetics , Case-Control Studies , Critical Illness , Enoxaparin/pharmacokinetics , Female , Humans , Injections, Subcutaneous , Intensive Care Units , Kidney Function Tests , Male , Middle Aged , Models, Biological , Prospective Studies , Thrombin/drug effects , Thrombin/metabolism , Thrombosis/drug therapy , Time Factors
14.
Dermatol Pract Concept ; 1(1): 21-4, 2011.
Article in English | MEDLINE | ID: mdl-24396715

ABSTRACT

Melanoma arising in a nevus spilus is rare. There are two distinct types of nevus spilus characterized by macular or papular speckles, respectively. We report the case of a melanoma that arose in association with a giant nevus spilus maculosus.

SELECTION OF CITATIONS
SEARCH DETAIL
...